The impact of a conjugate pneumococcal vaccine (Prevenar 13) on the epidemiology and aetiology of childhood pneumonia in the North East of England
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2016
Price : $35 *
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Community-acquired pneumonia; Pneumococcal infections
- Focus Therapeutic Use
- 17 Nov 2015 Accrual to date is 46% according to the United Kingdom Clinical Research Network record.
- 17 Nov 2015 Planned number of patients changed from 500 to 180, according to United Kingdom Clinical Research Network record.
- 13 Nov 2015 Accrual to date is 16% according to the United Kingdom Clinical Research Network record.